Loading…
← CockpitCompetitor Analysis › 301015.SZ Qingdao Baheal Medical Inc. Class AOpen in the cockpit ↗

Qingdao Baheal Medical Inc. Class A301015.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Qingdao firm that runs sales, marketing and distribution of branded medicines and supplements, including Dicare calcium, for brand owners.

Momentum leader 88
Mkt cap
$1.81B
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$56.5M
20-day average traded
Fwd P/E
21.0×
forward earnings
ROIC−WACC
+3.4 pp
WACC 6.4%
Hurdle
+5 pp
Req g minus delivered
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥23.22
1D-2.1%
1W-9.4%
1M+3.9%
3M-7.9%
6M+1.7%
YTD-1.6%
1Y-9.4%
ATR %6.7%
52w lowhigh19.3% off high

What Qingdao Baheal Medical does

Qingdao firm that runs sales, marketing and distribution of branded medicines and supplements, including Dicare calcium, for brand owners.

Is mainly paid to build and run brands rather than to make drugs, handling consumer education, doctor outreach, marketing and distribution for medicines and supplements such as the Dicare calcium line. Wholesale distribution and pharmacies add volume at lower returns, and it is deliberately trimming wholesale. Investments in innovative-drug developers are a newer thread.

Products and services

  • Brand operation (Dicare, Bite, Halle and partner lines)
  • Wholesale distribution
  • Retail pharmacy and e-commerce
  • Innovative-drug investments

Customers

  • Pharmaceutical brand owners such as Takeda and Roc
  • Hospitals and pharmacy chains
  • Consumers via retail and e-commerce

Where it sits in the supply chain

  • Health Care
  • Pharmaceutical commercialisation
  • Brand operation, distribution and…

What could go right

  • Calcium supplement range for children and teens
  • Innovative-drug investments and partnerships

What could go wrong

  • Dependence on partner brand rights
  • Wholesale shrinkage and drug-pricing reform

Moat: narrow (distribution, brand). Hospital and pharmacy channel reach plus long-run consumer brands such as Dicare; depends on partners renewing brand rights.

Headquarters: Qingdao, China · Employees: 3,498

Named competitors

Qingdao Baheal Medical at a glance

Size Qingdao Baheal Medical (301015.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.81B, the 1274th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.22 on 18 Nov 2026.

Performance Over six months the shares gained 1.7%, against -10.4% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue fell 6.2% over the last twelve months (peer median +6.7%); the operating margin is 7.8% (peer median 9.9%).

Valuation It trades at 21.0× forward earnings against a peer median of 19.1× (8th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.4 points above its cost of capital (6.4% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026301015.SZ 103Peer median 92
Six months, rebased to 100: Qingdao Baheal Medical against the median of its 20 peers (local-currency closes).

Qingdao Baheal Medical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥7.10BCN¥7.47BCN¥8.06BCN¥8.22BCN¥7.48B
Revenue growth—-7%-2%+10%—
Gross profitCN¥2.80BCN¥2.71BCN¥2.79BCN¥2.66BCN¥2.01B
EBITDAn/aCN¥854MCN¥1.07BCN¥1.13BCN¥773M
Net incomeCN¥238MCN¥475MCN¥692MCN¥712MCN¥507M
Free cash flowCN¥296MCN¥653MCN¥518MCN¥619MCN¥204M
Capital expenditureCN¥219MCN¥289MCN¥304MCN¥185MCN¥105M
Total debtCN¥4.11BCN¥3.86BCN¥2.80BCN¥1.80BCN¥1.77B

Quarterly statements and history in the cockpit →

Qingdao Baheal Medical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%-10%0%+10%RARE002399ZYME0000283933605507ETON300573600664AGIODMP000908COHANCE600211300009PFIZERNATCOPHARMALIVUS688166MAZE301015.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Qingdao Baheal Medical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×RARE002399ZYME0000283933605507ETON300573600664COHANCENATCOPHARM688166301015.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Qingdao Baheal Medical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%002399000028ETON300573NATCOPHARM688166301015.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Qingdao Baheal Medical is the large dot.

Qingdao Baheal Medical competitors and peer comparison

Head to head with its named competitors (301015.SZ vs 1099.HK vs 601607.SS vs 600998.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Qingdao Baheal Medical 301015.SZ$1.81B+2%-6%8%21.0×10.1%
Sinopharm 1099.HK$6.74B0%+3%3%6.2×-7.3%
Shanghai Pharmaceuticals 601607.SS$8.23B0%+4%3%11.2×-10.1%
Jointown Pharmaceutical 600998.SS$3.99B+7%+9%2%11.8×0.2%

How Qingdao Baheal Medical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Qingdao Baheal Medical against its 20 peers (data as of 18 Nov 2026)
Measure301015.SZPeer medianRank in peer set
1-month return+3.9%-1.0%6th highest of 21
6-month return+1.7%-10.4%8th highest of 21
Distance from 52-week high-19.3%-33.7%5th highest of 21
Revenue growth (TTM)-6.2%+6.7%5th lowest of 21
Operating margin7.8%9.9%11th highest of 21
Forward P/E21.0×19.1×8th most expensive of 18
Growth the price implies (Req g, 7 yrs)10.1%3.3%6th most demanding of 15
Growth delivered (Del g)+5.0%+8.1%4th lowest of 15
Hurdle (Req g minus delivered)+5.1 pp-9.0 pp4th most demanding of 15
ROIC minus cost of capital+3.4 pp-0.5 pp10th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%25.8×-0.7%+0.5%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a

Questions

Who are Qingdao Baheal Medical's main competitors?
Named competitors: Sinopharm Group (1099.HK), Shanghai Pharmaceuticals (601607.SS), Jointown Pharmaceutical (600998.SS). The cockpit's measured peer set (industry) also includes Ultragenyx Pharmaceutical (RARE), Shenzhen Hepalink Pharmaceutical (002399.SZ), Zymeworks (ZYME), China National Accord Medicines (000028.SZ), United Laboratories International (3933.HK), Guobang Pharma (605507.SS).
Is Qingdao Baheal Medical expensive compared with its peers?
On forward p/e it trades at 21.0× against a peer median of 19.1×, 8th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Qingdao Baheal Medical stock performed?
Over six months to 18 Nov 2026 the shares returned +1.7% against -10.4% for the median peer; over one year -9.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.